Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
Biotech
First Opinion
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Biotech
STAT+

With real estate deal, Sanofi Genzyme boosts its bottom line in hot market

By Tim LoganApril 23, 2019

Reprints
Ruby Wallau for STAT

CAMBRIDGE, Mass. — Sanofi Genzyme (SNY) makes most of its money developing really complicated drugs for rare diseases.

But for the next decade it will make a nice little profit in a far simpler way: by flipping its real estate.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Tim Logan

Tags

‘I’m going to prove you wrong’: How a D.C.…
‘I’m going to prove you wrong’: How a D.C. power couple used an ALS diagnosis to…
Our child received a devastating diagnosis before she was…
Our child received a devastating diagnosis before she was born. We decided to protect her
Why fentanyl is deadlier than heroin, in a single…
Why fentanyl is deadlier than heroin, in a single photo
Up and down the ladder: The latest comings and…
Up and down the ladder: The latest comings and goings
Pharmalittle: EU delays pharma legislation again; India cancels license…
Pharmalittle: EU delays pharma legislation again; India cancels license for maker of cough syrup linked to…
The surprising biomedical legacy of the Iraq War
The surprising biomedical legacy of the Iraq War

Recommended Stories